
|Articles|September 14, 2015
- Squamous NSCLC
- Volume 1
- Issue 1
Evolving Paradigms in Squamous NSCLC: Conclusion
Author(s)Staff Writer
Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
Advertisement
This article is Part III of a series. View parts I and II:Evolving Paradigms in Squamous NSCLC> >
Articles in this issue
about 10 years ago
Cancer Immunotherapy: Evolving Treatment Options in Squamous NSCLCabout 10 years ago
Evolving Paradigms in Squamous NSCLC: Referencesover 10 years ago
Evolving Paradigms in Squamous NSCLC: IntroductionAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5






































